PRESS RELEASE

Press Release

AstraZeneca Joins the Radiosurgery Society’s Sponsorship Alliance as First Pharmaceutical Partner

Collaboration Will Help Further the Advancement of Combination Therapies Aimed at Improving Cancer Outcomes and Quality of Life

SAN JOSE, Calif., August 31, 2022 – The Radiosurgery Society (RSS), a non-profit medical society dedicated to advancing the science and clinical practice of radiosurgery, today announced that AstraZeneca, a global, science-led biopharmaceutical company with innovative medicines used by millions of patients worldwide, has joined the RSS Sponsorship Alliance, adding to the list of highly respected institutions, organizations, societies and corporations to support the advancement of stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT) and advancing therapies.

AstraZeneca marks the first pharmaceutical company to join the RSS Sponsorship Alliance, which currently includes leading academic/medical centers, physician groups, corporate/manufacturers and network affiliates dedicated to advancing cancer care.

As a leader in oncology and biopharmaceuticals, AstraZeneca brings an important medical oncology perspective to the RSS Sponsorship Alliance. As the intersection of immuno-oncology and radiation therapy continues to demonstrate significant potential in improving patient outcomes and quality of life, the importance of collaboration between pharmaceutical companies, medical device manufacturers and other clinical experts in the field becomes even more important. The Radiosurgery’s Sponsorship Alliance provides a platform for intellectually, scientifically and technologically rich collaboration between these parties.

"It is encouraging to see the Radiosurgery Society partnering with companies like AstraZeneca which recognize the importance of radiation therapy as a curative treatment for people with lung cancer,” said Drew Moghanaki, M.D., MPH, Professor and Chief of Thoracic Oncology, Department of Radiation Oncology at the David Geffen School of Medicine at UCLA.

For those interested in learning more about the intersection of various treatment approaches to advance patient care, particularly in the treatment of lung cancer, the Radiosurgery Society will be hosting a webinar titled “Shifting Landscapes in Stage III NSCLC: The Thin Red Line between Surgery & Radiation Therapy,” based upon the well-received presentation given at the 2022 RSS Scientific meeting earlier this year. The free webinar will be held on Thursday, October 13, 2022, at 11:00 AM PT/2:00 PM ET and will feature Dr. Moghanaki and Millie Das, M.D., Chief of Oncology at the VA Palo Alto Health Care System and Clinical Associate Professor at Stanford University. The webinar will be moderated by Nitin Ohri, M.D., M.S., Associate Professor, Department of Radiation Oncology at Montefiore Medical Group. Register Now for this free webinar.

As the professional organization for industry standards, scientific methods and clinical advancements in SRS and SBRT, the RSS welcomes sponsoring organizations as partners. The RSS Sponsorship Alliance, which was introduced in 2012, provides opportunities for RSS members to collaborate scientifically, and continues to expand its global impact and contribution to the advancement of the RSS mission.

At the RSS, we believe active collaboration is critical to the advancement of treatment techniques, patient care, safety standards, and associated therapies,” said Joanne Davis, Ph.D., Executive Director of the Radiosurgery Society. “The RSS brings together individuals, institutions, organizations, and corporations to exchange innovative ideas and experience, and we’re thrilled that AstraZeneca will now be a part of these important dialogues.”

As a member of the RSS Sponsorship Alliance, corporations receive world-wide exposure and gain access to a plethora of opportunities including education, clinical research programs, scientific meeting participation, sponsored webinars, custom focus groups and surveys, advisory meetings and much more.

Additional information on the RSS Sponsorship Alliance and its associated benefits is available at https://therss.org/about-rss/sponsorship-alliance. Companies or organizations interested in joining the RSS as a Sponsorship Alliance member should contact sponsorship@therss.org.

About the Radiosurgery Society®
The Radiosurgery Society (RSS) – a non-profit, independent, multi-disciplinary organization of surgeons, radiation oncologists, physicists, and allied professionals, who are dedicated to advancing the science and clinical practice of radiosurgery. Originally formed in 2002 and becoming 501(c)(6) in 2008, the Radiosurgery Society today (www.therss.org) represents members who perform stereotactic body radiotherapy and radiosurgery in hospitals and freestanding centers throughout the world.

Contacts:
Stephanie Tomei
the Radiosurgery Society®
PressRelease@therss.org

Interested in learning more about the Sponsorship Alliance?